An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2019
At a glance
- Drugs SC 006 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2018 Planned number of patients changed from 128 to 108.
- 11 May 2018 Planned number of patients changed from 108 to 128.